Trials / Completed
CompletedNCT04890509
A Study of Bemcentinib for the Treatment of COVID-19 in Hospitalised Patients
A Multicentre, Phase 2, Randomised Study to Assess the Efficacy and Safety of Bemcentinib for the Treatment of COVID-19 in Hospitalised Patients
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 115 (actual)
- Sponsor
- BerGenBio ASA · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study is to evaluate the efficacy of bemcentinib as an add-on therapies to standard of care (SoC) in participants hospitalized with coronavirus disease 2019 (COVID-19).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bemcentinib | Bemcentinib capsules will be administered orally. |
| OTHER | SoC | The SoC will be administered based on local guidelines. |
Timeline
- Start date
- 2020-10-20
- Primary completion
- 2021-05-25
- Completion
- 2021-05-25
- First posted
- 2021-05-18
- Last updated
- 2024-10-16
- Results posted
- 2024-10-16
Locations
12 sites across 2 countries: India, South Africa
Source: ClinicalTrials.gov record NCT04890509. Inclusion in this directory is not an endorsement.